AR110400A1 - Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer - Google Patents
Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncerInfo
- Publication number
- AR110400A1 AR110400A1 ARP170103582A ARP170103582A AR110400A1 AR 110400 A1 AR110400 A1 AR 110400A1 AR P170103582 A ARP170103582 A AR P170103582A AR P170103582 A ARP170103582 A AR P170103582A AR 110400 A1 AR110400 A1 AR 110400A1
- Authority
- AR
- Argentina
- Prior art keywords
- triazolopiridine
- amino
- compounds
- cancer treatment
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: R¹ es un anillo de ciclohexilo, tetrahidrofuranilo u oxanilo, cada uno de los cuales está opcionalmente sustituido por uno o más grupos seleccionados de hidroxilo, metoxi y metilo; y R² es hidrógeno o metilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436619P | 2016-12-20 | 2016-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110400A1 true AR110400A1 (es) | 2019-03-27 |
Family
ID=60937727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103582A AR110400A1 (es) | 2016-12-20 | 2017-12-19 | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10407446B2 (es) |
| EP (1) | EP3558997B1 (es) |
| JP (1) | JP6883653B2 (es) |
| KR (1) | KR102220971B1 (es) |
| CN (1) | CN110177791B (es) |
| AR (1) | AR110400A1 (es) |
| AU (1) | AU2017384388B2 (es) |
| BR (1) | BR112019012217B1 (es) |
| CA (1) | CA3046339C (es) |
| CL (1) | CL2019001714A1 (es) |
| CO (1) | CO2019007810A2 (es) |
| CR (1) | CR20190301A (es) |
| CY (1) | CY1124239T1 (es) |
| DK (1) | DK3558997T3 (es) |
| DO (1) | DOP2019000168A (es) |
| EA (1) | EA037745B1 (es) |
| EC (1) | ECSP19044159A (es) |
| ES (1) | ES2867274T3 (es) |
| HR (1) | HRP20210548T1 (es) |
| HU (1) | HUE054548T2 (es) |
| IL (1) | IL267158B (es) |
| JO (1) | JOP20190151B1 (es) |
| LT (1) | LT3558997T (es) |
| MA (1) | MA47079B1 (es) |
| MX (1) | MX390535B (es) |
| MY (1) | MY183036A (es) |
| NI (1) | NI201900062A (es) |
| NZ (1) | NZ755222A (es) |
| PE (1) | PE20191474A1 (es) |
| PH (1) | PH12019501350B1 (es) |
| PL (1) | PL3558997T3 (es) |
| PT (1) | PT3558997T (es) |
| RS (1) | RS61701B1 (es) |
| SI (1) | SI3558997T1 (es) |
| SM (1) | SMT202100225T1 (es) |
| TW (1) | TWI776835B (es) |
| UA (1) | UA123032C2 (es) |
| WO (1) | WO2018114999A1 (es) |
| ZA (1) | ZA201904695B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3558997T3 (pl) | 2016-12-20 | 2021-07-19 | Astrazeneca Ab | Związki amino-triazolopirydyny i ich zastosowanie w leczeniu nowotworu złośliwego |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020186211A1 (en) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Methods and compositions for treating polyoma virus infection |
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| EP3983542A2 (en) | 2019-06-17 | 2022-04-20 | CRISPR Therapeutics AG | Methods and compositions for improved homology directed repair |
| JP2023503931A (ja) * | 2019-11-22 | 2023-02-01 | メッドシャイン ディスカバリー インコーポレイテッド | Ｄｎａ－ｐｋ阻害剤としてのピリミドピロール系スピロ化合物及びその誘導体 |
| CA3159290A1 (en) * | 2019-11-25 | 2021-06-03 | Kevin X Chen | Pyrimidoimidazole compounds used as dna-pk inhibitors |
| PH12022551280A1 (en) | 2019-11-26 | 2024-01-08 | Primmune Therapeutics Inc | Tlr7 agonists |
| CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| CN113121574B (zh) * | 2019-12-31 | 2023-02-17 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的用途 |
| CN113493471B (zh) * | 2020-04-03 | 2024-06-11 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
| BR112022020962A2 (pt) * | 2020-04-17 | 2022-12-06 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivados de imidazolidinona e uso médico dos mesmos |
| WO2021213460A1 (zh) * | 2020-04-23 | 2021-10-28 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| KR20230017783A (ko) | 2020-04-28 | 2023-02-06 | 인텔리아 테라퓨틱스, 인크. | 시험관내 세포 전달 방법 |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
| WO2022064430A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| EP4263829A1 (en) | 2020-12-17 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
| WO2022199547A1 (zh) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| TW202309034A (zh) | 2021-04-17 | 2023-03-01 | 美商英特利亞醫療公司 | Dna依賴性蛋白質激酶抑制劑以及其組合物及用途 |
| WO2022242658A1 (zh) * | 2021-05-19 | 2022-11-24 | 南京明德新药研发有限公司 | 杂环取代的嘌呤酮衍生物的盐型及晶型 |
| CN117377676A (zh) * | 2021-06-29 | 2024-01-09 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN116023395B (zh) * | 2021-10-25 | 2025-07-15 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| CN120435459A (zh) | 2022-12-06 | 2025-08-05 | 阿斯利康(瑞典)有限公司 | Polq抑制剂 |
| WO2025023957A1 (en) * | 2023-07-21 | 2025-01-30 | Wei Zhong | Substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8h-purin-8-one compounds and their use in treating cancer |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025181336A1 (en) | 2024-03-01 | 2025-09-04 | Cellectis Sa | Compositions and methods for hbb-editing in hspc |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| CN1922141A (zh) | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| AU2006205851A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| CA2625109A1 (en) | 2005-10-13 | 2007-04-19 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US7919490B2 (en) * | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| KR101504669B1 (ko) | 2006-10-19 | 2015-03-20 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| NZ584138A (en) | 2007-08-23 | 2011-10-28 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| KR101942212B1 (ko) | 2010-02-03 | 2019-01-24 | 시그날 파마소티칼 엘엘씨 | Ｔｏｒ 키나제 억제자에 대한 민감성 예측 바이오마커로서 ｌｋｂ1 돌연변이의 동정 |
| CN102869358B (zh) | 2010-04-13 | 2016-03-23 | 诺华股份有限公司 | 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合 |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| TWI629983B (zh) | 2011-10-19 | 2018-07-21 | 標誌製藥公司 | 以ｔｏｒ激酶抑制劑治療癌症 |
| US20130245029A1 (en) * | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| AU2014223501A1 (en) | 2013-02-28 | 2015-09-17 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| NO2714752T3 (es) | 2014-05-08 | 2018-04-21 | ||
| PL3558997T3 (pl) | 2016-12-20 | 2021-07-19 | Astrazeneca Ab | Związki amino-triazolopirydyny i ich zastosowanie w leczeniu nowotworu złośliwego |
-
2017
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/en active Active
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 PH PH1/2019/501350A patent/PH12019501350B1/en unknown
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 MX MX2019007189A patent/MX390535B/es unknown
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 SM SM20210225T patent/SMT202100225T1/it unknown
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es active IP Right Grant
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active Active
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/en not_active Ceased
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 CA CA3046339A patent/CA3046339C/en active Active
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CL2020001234A1 (es) | Compuestos moduladores de sting y métodos de elaboración y uso. | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| AR094784A1 (es) | Compuestos de tubulisina, métodos para obtenerlos y uso | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR098912A1 (es) | Inhibidores de syk | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| EA201591486A1 (ru) | Соединения имидазопиридина | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX381970B (es) | Derivado de sulfonamida y composición farmacéutica que contiene el mismo. | |
| MX2018003590A (es) | Compuestos y metodos para la inhibicion de jak. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| NI201800065A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| AR103316A1 (es) | Inhibidores de dihidroquinazolina de terminasa viral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |